Publications by authors named "Derlis Gonzalez"

Claim this Profile
L
Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease.
Derralynn Hughes, Derlis Gonzalez, Gustavo Maegawa, John A Bernat, Myrl Holida

Genet Med· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study.
Myrna Candelaria, Derlis E González, Marcia Torresan Delamain, Daniel Oscar Bär, Surender Kumar Beniwal

Leuk Lymphoma· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial.
Raphael Schiffmann, Ozlem Goker-Alpan, Myrl Holida, Pilar Giraldo, Laura Barisoni, Derlis Gonzalez

J Inherit Metab Dis· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Myrna Candelaria, Derlis Gonzalez, Francisco Javier Fernández Gómez, Alexandra Paravisini, Ana Del Campo García

Cancer Chemother Pharmacol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
Ari Zimran, Deborah Elstein, Derlis E Gonzalez, Elena A Lukina, Yulin Qin

Blood Cells Mol Dis· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to request by journal editorship from Blood Cells, Molecules and Diseases in reference to a "Dear Editor" letter to the Pastores et al. paper, 2016.
Gregory M Pastores, Hadhami Ben Turkia, Derlis E Gonzalez, Hiroyuki Ida, Azaza A G Tantawy

Blood Cells Mol Dis· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.
Gregory M Pastores, Hadhami Ben Turkia, Derlis E Gonzalez, Hiroyuki Ida, Azza A G Tantawy

Blood Cells Mol Dis· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long-term data from phase III clinical trials.
Derralynn A Hughes, Derlis E Gonzalez, Elena A Lukina, Atul Mehta, Madhulika Kabra

Am J Hematol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
Derlis E Gonzalez, Hadhami Ben Turkia, Elena A Lukina, Isaac Kisinovsky, Marie-Françoise Ben Dridi

Am J Hematol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
Hadhami Ben Turkia, Derlis E Gonzalez, Norman W Barton, Ari Zimran, Madhulika Kabra

Am J Hematol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis